| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Following the positive outcome of a recent agency meeting, the Company will continue to work closely with the FDA to bring this pioneering healthcare product to market
PLEASANTON, Calif., Sept. 3, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) announced today that a productive in-person meeting with the FDA on August 15, 2024, resulted in a positive outcome regarding the EvieMED Ring's wellness features and metrics. Following this development, the Company will be working with the agency to move forward with the review process. The EvieMED Ring is a wearable device designed to not only provide medical device functionality through its pulse oximetry feature, but also offer numerous wellness metrics related to sleep, activity and logging of mood, energy and other characteristics.
Posted In: MOVE
